- Home
- PRME vs GLUE Comparison
PRME vs GLUE Comparison
Compare PRME & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- GLUE
- Stock Information
- Founded
- PRME 2019
- GLUE 2019
- Country
- PRME United States
- GLUE United States
- Employees
- PRME N/A
- GLUE N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- GLUE Health Care
- Exchange
- PRME Nasdaq
- GLUE Nasdaq
- Market Cap
- PRME 424.9M
- GLUE 475.5M
- IPO Year
- PRME 2022
- GLUE 2021
- Fundamental
- Price
- PRME $2.90
- GLUE $6.93
- Analyst Decision
- PRME Strong Buy
- GLUE Buy
- Analyst Count
- PRME 9
- GLUE 3
- Target Price
- PRME $13.13
- GLUE $12.67
- AVG Volume (30 Days)
- PRME 1.3M
- GLUE 1.8M
- Earning Date
- PRME 11-12-2024
- GLUE 11-07-2024
- Dividend Yield
- PRME N/A
- GLUE N/A
- EPS Growth
- PRME N/A
- GLUE N/A
- EPS
- PRME N/A
- GLUE N/A
- Revenue
- PRME $800,000.00
- GLUE $14,975,000.00
- Revenue This Year
- PRME N/A
- GLUE N/A
- Revenue Next Year
- PRME $426.55
- GLUE N/A
- P/E Ratio
- PRME N/A
- GLUE N/A
- Revenue Growth
- PRME N/A
- GLUE N/A
- 52 Week Low
- PRME $2.56
- GLUE $3.21
- 52 Week High
- PRME $9.80
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- PRME 41.76
- GLUE 39.61
- Support Level
- PRME $2.56
- GLUE $6.15
- Resistance Level
- PRME $3.04
- GLUE $7.95
- Average True Range (ATR)
- PRME 0.25
- GLUE 0.88
- MACD
- PRME -0.01
- GLUE -0.34
- Stochastic Oscillator
- PRME 36.17
- GLUE 17.18
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.